{"entity":{"id":"nct07258979","kind":"trial","name":"A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.","aka":[],"tldr":"A phase 1/2 trial of YL201, Toripalimab, Cisplatin in nasopharyngeal carcinoma, run by MediLink Therapeutics (Suzhou) Co., Ltd., now recruiting.","summary":"A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma. is a phase 1/2 interventional study registered as NCT07258979 by MediLink Therapeutics (Suzhou) Co., Ltd., with 202 participants planned, started 2025-11-05 and due to reach its primary completion in 2028-02. Interventions recorded: YL201, Toripalimab, Cisplatin. Conditions listed: Recurrent or Metastatic Nasopharyngeal Carcinoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07258979","url":"https://clinicaltrials.gov/study/NCT07258979"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nasopharyngeal","locoregionally-advanced-nasopharyngeal-carcinoma","recurrent-metastatic-nasopharyngeal-carcinoma"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["yl201","toripalimab","cisplatin"],"companies":["medilink"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07258979","phase":"1/2","setting":"A Multicenter, Open-label, Phase Ib/II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 Combined With Toripalimab, With or Without Cisplatin, in Subjects With Recurrent or Metastatic Nasopharyngeal Carcinoma.","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","started":"2025-11-05","startedType":"actual","enrolled":202,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07258979/","neighbours":{"cancer":[{"id":"locoregionally-advanced-nasopharyngeal-carcinoma","kind":"cancer","name":"Locoregionally advanced nasopharyngeal carcinoma (stage III to IVA)","route":"/cancers/locoregionally-advanced-nasopharyngeal-carcinoma/"},{"id":"nasopharyngeal","kind":"cancer","name":"Nasopharyngeal carcinoma","route":"/cancers/nasopharyngeal/"},{"id":"recurrent-metastatic-nasopharyngeal-carcinoma","kind":"cancer","name":"Recurrent and metastatic nasopharyngeal carcinoma","route":"/cancers/recurrent-metastatic-nasopharyngeal-carcinoma/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/"},{"id":"yl201","kind":"drug","name":"YL201","route":"/drugs/yl201/"}],"company":[{"id":"medilink","kind":"company","name":"MediLink Therapeutics","route":"/companies/medilink/"}]}}